Literature DB >> 14767208

Thoracic lymphangiomatosis in a child.

Ofelia A Alvarez1, Ingrid Kjellin, Craig W Zuppan.   

Abstract

An 8-year-old boy who presented with a mediastinal mass, pulmonary infiltrates, and disseminated intravascular coagulation was diagnosed with lymphangiomatosis. Despite medical management, he developed multiple organ failure and died. The authors discuss the diagnostic findings, medical management, and pathology and review 52 additional cases of thoracic lymphangiomatosis from the literature. Patients presented with chylothorax (49%), a mass (47%), pulmonary infiltrates (45%), bone lesions (39%), splenic lesions (19%), cervical involvement (15%), disseminated intravascular coagulation (9%), and skin involvement (7%). Children (<16 years) had a worse prognosis than older patients (39% vs. 0% mortality). All patients who died had either parenchymal lung involvement or pleural effusion. Thoracic lymphangiomatosis should be included in the differential diagnosis of a mediastinal mass with pulmonary findings.

Entities:  

Mesh:

Year:  2004        PMID: 14767208     DOI: 10.1097/00043426-200402000-00018

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  16 in total

1.  Serious complications of pulmonary biopsy in a boy with chylopericardium and suspected pulmonary lymphangiomatosis.

Authors:  Esther Harnisch; Ram Sukhai; Anne Marie Oudesluys-Murphy
Journal:  BMJ Case Rep       Date:  2010-05-06

2.  Thoracic lymphangiomatosis with massive chylothorax after a tumor biopsy and with disseminated intravenous coagulation--lymphoscintigraphy, an alternative minimally invasive imaging technique: report of a case.

Authors:  Suguru Fukahori; Tomomitsu Tsuru; Kimio Asagiri; Hirotaka Nakamizo; Takahiro Asakawa; Hiroaki Tanaka; Yoshiaki Tanaka; Jun Akiba; Hirohisa Yano; Minoru Yagi
Journal:  Surg Today       Date:  2011-07-12       Impact factor: 2.549

3.  Efficacy of systemic sirolimus in the treatment of generalized lymphatic anomaly and Gorham-Stout disease.

Authors:  Kiersten W Ricci; Adrienne M Hammill; Paula Mobberley-Schuman; Stephen C Nelson; Julie Blatt; Julia L Glade Bender; Catherine C McCuaig; Anna Synakiewicz; Ilona J Frieden; Denise M Adams
Journal:  Pediatr Blood Cancer       Date:  2019-01-22       Impact factor: 3.167

4.  Diffuse pulmonary lymphangiomatosis.

Authors:  Kunal C Kadakia; Sandeep M Patel; Eunhee S Yi; Andrew H Limper
Journal:  Can Respir J       Date:  2013 Jan-Feb       Impact factor: 2.409

5.  Sudden death of a 14-year-old girl with lymphangiomatosis.

Authors:  Tomoki Nakagawa; Takahisa Koizumi; Kana Oiwa; Chie Inomoto; Go Ogura; Ryota Masuda; Tomohiro Yamashita; Naoya Nakamura; Masayuki Iwazaki
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-07-23

6.  Kaposiform lymphangiomatosis: a distinct aggressive lymphatic anomaly.

Authors:  Stacy E Croteau; Harry P W Kozakewich; Antonio R Perez-Atayde; Steven J Fishman; Ahmad I Alomari; Gulraiz Chaudry; John B Mulliken; Cameron C Trenor
Journal:  J Pediatr       Date:  2013-11-16       Impact factor: 4.406

7.  Pulmonary lymphangiomatosis.

Authors:  Melissa N Satria; Gustavo Pacheco-Rodriguez; Joel Moss
Journal:  Lymphat Res Biol       Date:  2011       Impact factor: 2.589

8.  Successful surgical treatment of thoracic multiorgan lymphangiomatosis.

Authors:  Ina Steinacher; Bernd Lamprecht; Markus Lobendanz; Heinz Zoller; Phillippe Dartevelle; Elie Fadel; Michael Studnicka
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

9.  Craniofacial CT findings of Gorham-Stout disease and generalized lymphatic anomaly.

Authors:  Hiroki Kato; Michio Ozeki; Toshiyuki Fukao; Masayuki Matsuo
Journal:  Neuroradiology       Date:  2016-04-28       Impact factor: 2.804

10.  Invasive lymphangioma of the lung manifesting as a large pulmonary mass with hemoptysis: report of a case.

Authors:  Jun Nakajima; Akiteru Goto; Shinichi Takamoto; Tomohiro Murakawa; Takeshi Fukami; Masashi Kusakabe
Journal:  Surg Today       Date:  2007-04-30       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.